Drug Target Review

JULY 30, 2025

Radioligand therapy (RLT) has emerged as a powerful modality in oncology, offering highly targeted delivery of radiation to cancer cells while sparing healthy tissues. Although RLT has already demonstrated success in certain haematological and prostate cancers, its application in solid tumours has historically faced a number of biological and technical challenges – from limited tissue penetration to off-target toxicity, particularly in organs like the kidneys.

Clinical Trials

Broad Institute

JULY 29, 2025

Collaboration aims to reduce animal use in drug safety testing By Leah Eisenstadt July 29, 2025 Breadcrumb Home Collaboration aims to reduce animal use in drug safety testing OASIS consortium is evaluating omics tools in cells, including Cell Painting and transcriptomics, to predict liver toxicity of potential new medicines and agrochemicals. By Leah Eisenstadt July 29, 2025 Credit: Axiom Bio, via Cell Painting Gallery (CC0 License) Members of the OASIS Consortium are employing the Cell Painting

Animal Testing

Covalent Modifiers

JULY 24, 2025

Yoav Shamir, Nir London bioRxiv 2025.03.19.642201 doi: [link] Recent years have seen an explosion in the prominence of covalent inhibitors as research and therapeutic tools. However, a lag in application of computational methods for covalent docking slows progress in this field. AI models such as AlphaFold3 have shown accuracy in ligand pose prediction but were never assessed for virtual screening.

Research

Science Daily: Pharmacology News

JULY 25, 2025

Millipedes, often dismissed as creepy crawlies, may hold the secret to future painkillers and neurological drugs. Researchers at Virginia Tech discovered unique alkaloid compounds in the defensive secretions of a native millipede species. These complex molecules, which cause disorientation in ants, interact with human neuroreceptors linked to pain and cognition.

Therapies

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Drug Target Review

JULY 24, 2025

Antibody therapies have transformed cancer treatment, yet their limits are becoming increasingly clear – particularly when tumours evolve, evade immune detection or develop resistance to existing drugs. For Dr Jhong-Jhe ‘JJ’ You, Vice President of Antibody Discovery at AP Biosciences, these challenges are not setbacks. They are starting points. With a background in neurobiology, immuno-oncology and bispecific engineering, JJ now leads the development of antibody candidates designed to go further

Immune Response

Chemical Biology and Drug Design

JULY 25, 2025

Novel 1,2,3-triazole derivatives incorporating a 4-iodosulfonamide moiety were synthesized. Their antioxidant properties were evaluated using DPPH, ABTS, and CUPRAC methods. The inhibitory activity of the compounds against cholinesterases (AChE and BuChE) was investigated. An investigation of their anticancer properties against Caco-2 and PC3 cancer cell lines was also conducted.

Pharmaceuticals

Covalent Modifiers

JULY 28, 2025

Bing Zhao, Sha Xu, Shiqing Zhou, Xiangru Jiang, Ailin Jiang, Hongrui Lei, Xin Zhai Bioorganic Chemistry, 163, 2025, 108800, [link] [link] the past two decades, covalent inhibitors have undergone a remarkable resurgence in drug discovery. Currently, targeting non-catalytic cysteine residues with acrylamide and other α,β-unsaturated carbonyl compounds is a predominate strategy, especially in the protein kinase field.

Research

Science Daily: Pharmacology News

JULY 25, 2025

A virus from humble black-eyed peas is showing extraordinary promise in the fight against cancer. Unlike other plant viruses, the cowpea mosaic virus (CPMV) can awaken the human immune system and transform it into a cancer-fighting powerhouse, without infecting human cells. By comparing it to a similar, but ineffective, virus, researchers uncovered that CPMV uniquely triggers potent interferons and immune responses, making it a low-cost, plant-grown immunotherapy on the fast track toward clinica

Virus

The Open Targets Blog

JULY 23, 2025

How can you work out the function of a particular gene or protein across different cell types and functions? If you perturb it—modify it and observe the consequences—you can start to unravel what its biological role might be, and determine whether the effects are unique to one cell type or whether they propagate across different cell contexts.

Bioinformatics

Chemical Biology and Drug Design

JULY 23, 2025

Liver cancer is a form of aggressive tumor, with HCC accounting for most of its occurrences. Traditional Chinese herbal medicines are well-known for their low risks of adverse events and anticancer effects. HMA, the main active ingredient of Hedyotis diffusa Willd , has been shown to suppress the growth of several malignancies. Therefore, this study examined the effects of HMA in HCC.

Protein Expression

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Covalent Modifiers

JULY 23, 2025

Fernando, M. C., Craven, G. B., & Shokat, K. M. Small GTPases, 2024 15(1), 1–7. [link] KRAS is the most frequently mutated oncogene in human cancer. In multiple types of cancer, a missense mutation at codon 12 substitutes a glycine for a cysteine, causing hyperactivation of the GTPase and enhanced MAPK signalling. Recent drug discovery efforts culminating from work during the past decade have resulted in two FDA-approved inhibitors, sotorasib and adagrasib, which target the KRASG12C mutant a

FDA Approval

Science Daily: Pharmacology News

JULY 26, 2025

A groundbreaking study has revealed that the mass administration of ivermectin—a drug once known for treating river blindness and scabies—can significantly reduce malaria transmission when used in conjunction with bed nets.

Drugs

Drug Target Review

JULY 28, 2025

When discussing how newer AI technologies like large language models (LLMs) could contribute to toxicity prediction, Hosseini-Gerami identified two key applications: 1. Improved scientist–data interaction: “Once we have all these datasets, have run these algorithms and have some outcomes and outputs, how can a scientist really engage with that information and use it to make a decision on what to do next?

Drugs

Codon

JULY 28, 2025

A gene is the essential hereditary unit that passes traits from parents to offspring; a segment of DNA containing instructions for making a specific protein or molecule that performs a particular function in your body. And yet, despite being fundamental to our flourishing, genes can be broken. Researchers have identified nearly 10,000 monogenic diseases , or conditions caused by errors in a single gene.

Immune Response

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drugs.com

JULY 24, 2025

THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has upgraded a recall of a commonly prescribed thyroid medication due to what it described as "subpotent" active ingredients. The recall of more than 160,000 bottles of.

FDA

Covalent Modifiers

JULY 25, 2025

Xue Li, Ru Li, Xiaoxia Zhu et al. Research Square Preprint, 23 July 2025, [link] Orelabrutinib is a highly selective, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). It has shown promising results in animal models, indicating potential for treating systemic lupus erythematosus (SLE). A multicentre, double-blind, randomised, placebo-controlled, phase Ib/IIa trial (NCT04305197) was conducted.

Treatment

Science Daily: Pharmacology News

JULY 25, 2025

Fermenting stevia with a banana leaf-derived probiotic turns it into a powerful cancer-fighting agent that kills pancreatic cancer cells while sparing healthy ones. The secret lies in a metabolite called CAME, produced through microbial transformation.

Drug Target Review

JULY 30, 2025

The journey of cell and gene therapies from preclinical discovery to clinical trials is complex and challenging, impacting every team member involved, from researchers in the lab to patients receiving treatment. As CGT trials require innovative and flexible solutions, the need for technology such as interactive response technology (IRT) has become crucial in streamlining trial workflows, ensuring data integrity, and maintaining regulatory compliance as therapies advance from preclinical stages.

Clinical Development

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Crown Bioscience

JULY 28, 2025

Antibody-drug conjugates (ADCs) are among the most exciting advances in target cancer therapy. They combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs to focus treatment on malignant cells while reducing damage to healthy cells.

Small Molecule

Sygnature Discovery

JULY 24, 2025

Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment. In today’s demanding drug discovery landscape, accelerating time to value inflection remains a top industry priority.

Laboratories

Drugs.com

JULY 24, 2025

THURSDAY, July 24, 2025 — Insulin delivered by nasal spray might be a potential treatment for Alzheimer’s disease, a new study says. An insulin nasal spray effectively reached key memory regions in the brains of a small group of older.

Treatment

Science Daily: Pharmacology News

JULY 23, 2025

Scientists have discovered a sugar compound from deep-sea bacteria that can destroy cancer cells in a dramatic way. This natural substance, produced by microbes living in the ocean, causes cancer cells to undergo a fiery form of cell death, essentially making them self-destruct. In lab tests and in mice with liver cancer, the compound not only stopped tumors from growing, but also activated the immune system to fight back.

Treatment

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Chemical Biology and Drug Design

JULY 29, 2025

A drug repurposing strategy was applied against M. abscessus, through a virtual screening of FDA approved drugs on salicylate synthase. Eleven potential ligands were found; among these, three were confirmed as potent inhibitors of the enzyme. ABSTRACT Non-tuberculous mycobacteria (NTM) are opportunistic pathogens that lead to severe, persistent infections, particularly in immunocompromised or vulnerable individuals.

FDA Approval

H1 Blog

JULY 28, 2025

More Information, Same Enrollment Challenges In clinical trial feasibility, we face a counterintuitive reality: despite unprecedented access to healthcare professional data, identifying the right investigators and predicting enrollment success has become increasingly challenging. This paradox, highlighted in a recent Life Sciences DNA podcast featuring Ariel Katz, co-founder and CEO of H1, in conversation with Dr.

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 29, 2025

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical tests and is building a manufacturing network in support.

Drugs.com

JULY 24, 2025

THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic hand eczema (CHE). CHE is common condition marked by redness, itching and cracking on the.

FDA Approval

Science Daily: Pharmacology News

JULY 23, 2025

HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells, offering hope for the first preventative and curative treatments.

Virus

New Drug Approvals

JULY 25, 2025

Vamorolone CAS 13209-41-1 Molecular Weight 356.46 Formula C 22 H 28 O 4 Agamree 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione VBP-15 free alcohol (8 S ,10 S ,13 S ,14 S ,16 R ,17 R )-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6 H -cyclopenta[a]phenanthren-3-one (16alpha)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta

FDA

PPD

JULY 29, 2025

Biopharma and biotech industries are facing remarkable challenges as the cost of developing new drugs has surged dramatically and clinical trial timelines have extended significantly. For example, over the past decade, the average time required to complete a clinical trial has increased by approximately 20-30%. These elongated timelines are contributing to soaring costs, with the average cost of developing a new drug rising to approximately $2.6 billion (versus $1-1.5 billion just a decade ago).

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 29, 2025

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five drugs that no longer fit its plans.

Drugs

Collaborative Drug

JULY 24, 2025

CDD Vault Update (July #2 2025) Search Inventory by Molecule & Batch Fields, Protocol Plate Locations, Stoichiometry Table Debiting, Synonym Links in ELN, Chemical Properties in Structure Editor

Drug Patent Watch

JULY 28, 2025

Uncovering the Secret Formulas: How Drug Patents Reveal the Competition's Playbook As the pharmaceutical industry continues to evolve, companies are under increasing pressure to innovate and stay ahead of the curve. But what if the key to unlocking your competitors' strategies lies in plain sight – hidden in the complex web of drug patents? A new analysis from Drug Patent Watch reveals the surprising ways in which competitors are using patent data to inform their formulation strategies.

Drugs

BioPharma Drive: Drug Pricing

JANUARY 2, 2025

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky year.

Clinical Trials